# Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

> **NCT06390982** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- RECTAL NEOPLASMS
- Rectal Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06390982
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2025-12
- **Final completion:** 2028-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390982, "Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06390982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*